A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.
In this interview, we speak to Dr. Frank Scheer and Dr. Sarah Chellappa about their latest research that investigated the effect meal times has on glucose intolerance.